These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39392882)

  • 1. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity.
    Fan T; Xu C; Wu J; Cai Y; Cao W; Shen H; Zhang M; Zhu H; Yang J; Zhu Z; Ma X; Ren J; Huang L; Li Q; Tang Y; Yu B; Chen C; Xu M; Wang Q; Xu Z; Chen F; Liang S; Zhong Z; Jamroze A; Tang DG; Li H; Dong C
    Sci Adv; 2024 Oct; 10(41):eadn9961. PubMed ID: 39392882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
    Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
    Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A liposomal RNA vaccine inducing neoantigen-specific CD4
    Salomon N; Vascotto F; Selmi A; Vormehr M; Quinkhardt J; Bukur T; Schrörs B; Löewer M; Diken M; Türeci Ö; Sahin U; Kreiter S
    Oncoimmunology; 2020 Jun; 9(1):1771925. PubMed ID: 32923128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
    Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
    Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
    Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
    Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma.
    Zhang Y; Lin Z; Wan Y; Cai H; Deng L; Li R
    Front Immunol; 2019; 10():2472. PubMed ID: 31749795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
    Lam H; McNeil LK; Starobinets H; DeVault VL; Cohen RB; Twardowski P; Johnson ML; Gillison ML; Stein MN; Vaishampayan UN; DeCillis AP; Foti JJ; Vemulapalli V; Tjon E; Ferber K; DeOliveira DB; Broom W; Agnihotri P; Jaffee EM; Wong KK; Drake CG; Carroll PM; Davis TA; Flechtner JB
    Cancer Discov; 2021 Mar; 11(3):696-713. PubMed ID: 33504579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
    PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.
    Zhang Y; Jiang L; Huang S; Lian C; Liang H; Xing Y; Liu J; Tian X; Liu Z; Wang R; An Y; Lu F; Pan Y; Han W; Li Z; Yin F
    Adv Sci (Weinh); 2024 Jun; 11(24):e2307754. PubMed ID: 38605600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant ferritin-based nanoparticles as neoantigen carriers significantly inhibit tumor growth and metastasis.
    Zheng W; Li S; Shi Z; Su K; Ding Y; Zhang L; Tang Q; Han J; Zhao H; Wang F; Zhang H; Hong Z
    J Nanobiotechnology; 2024 Sep; 22(1):562. PubMed ID: 39272180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and clinical development of neoantigen vaccines.
    Li L; Goedegebuure SP; Gillanders WE
    Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.
    Aurisicchio L; Salvatori E; Lione L; Bandini S; Pallocca M; Maggio R; Fanciulli M; De Nicola F; Goeman F; Ciliberto G; Conforti A; Luberto L; Palombo F
    J Exp Clin Cancer Res; 2019 Feb; 38(1):78. PubMed ID: 30764846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy.
    Zhang W; Shi X; Huang S; Yu Q; Wu Z; Xie W; Li B; Xu Y; Gao Z; Li G; Qian Q; He T; Zheng J; Zhang T; Tong Y; Deng D; Gao X; Tian H; Yao W
    Cancer Immunol Immunother; 2024 Oct; 73(12):245. PubMed ID: 39358493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
    Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
    Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.